Brentuximab vedotin

(Adcetris®)

Adcetris®

Latest News

loading GIF

Drug updated on 5/7/2024

Dosage FormInjection (intravenous; 50 mg)
Drug ClassCD30-directed antibody-drug conjugates
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • For the treatment of previously untreated Stage III or IV classical Hodgkin lymphoma (cHL), in combination with doxorubicin, vinblastine, and dacarbazine in adult patients.
  • For the treatment of classical Hodgkin lymphoma (cHL) at high risk of relapse or progression as postautologous hematopoietic stem cell transplantation (auto-HSCT) consolidation in adult patients.
  • For the treatment of classical Hodgkin lymphoma (cHL) after failure of auto-HSCT or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not auto-HSCT candidates in adult patients.
  • For the treatment of previously untreated systemic anaplastic large cell lymphoma (sALCL) or other CD30-expressing peripheral T-cell lymphomas (PTCL), including angioimmunoblastic T-cell lymphoma and PTCL not otherwise specified, in combination with cyclophosphamide, doxorubicin, and prednisone in adult patients.
  • For the treatment of systemic anaplastic large cell lymphoma (sALCL) after failure of at least one prior multi-agent chemotherapy regimen in adult patients.
  • For the treatment of primary cutaneous anaplastic large cell lymphoma (pcALCL) or CD30-expressing mycosis fungoides (MF) who have received prior systemic therapy in adult patients.

Summary
This AI-generated content is provided without warranty and may be inaccurate or outdated; it should be used only as a research starting point, with no liability accepted for reliance on it. Learn more.

  • Brentuximab vedotin (Adcetris) is indicated for the treatment of various types of lymphoma, including previously untreated Stage III or IV classical Hodgkin lymphoma (cHL), cHL at high risk of relapse or progression post-autologous hematopoietic stem cell transplantation, and systemic anaplastic large cell lymphoma after failure of at least one prior multi-agent chemotherapy regimen.
  • The information was derived from 10 systematic reviews/meta-analyses. These studies provided a comparison between brentuximab vedotin and other drugs based on safety and effectiveness in treating different subtypes of lymphomas.
  • In terms of effectiveness in Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL), brentuximab vedotin has shown superior efficacy as a salvage treatment compared to salvage chemotherapy post-autologous stem cell transplantation. It achieved an overall response rate (ORR) of 62.6% and a complete response rate (CR) of 32.9% after four treatment cycles with meaningful outcomes for progression-free survival rates.
  • Regarding its safety profile, common adverse events associated with brentuximab vedotin were hematological toxicities such as neutropenia, anemia, thrombocytopenia, grade ≥3 peripheral neuropathy, which aligns with the known side-effect profile; it also significantly increased the risk of all-grade peripheral sensory neuropathy, pyrexia, nausea, vomiting, diarrhea, and alopecia when compared to non-brentuximab therapies.
  • For advanced-stage Hodgkin Lymphoma patients, the combination therapy involving brentuximab vedotin showed improved efficacy over the ABVD regimen while maintaining tolerability; however, no direct comparison data was available against the BEACOPP regimen, but A+AVD appeared to be a more tolerable option.
  • Brentuximab vedotin-containing regimens demonstrated high response rates with manageable toxicity profiles in older adults, although attention to specific toxicities such as peripheral neuropathy is crucial.

Product Monograph / Prescribing Information

Document TitleYearSource
Adcetris (brentuximab vedotin) Prescribing Information. 2023Seattle Genetics Inc., Bothell, WA

Systematic Reviews / Meta-Analyses

Document TitleYearSource
A systematic literature review of the epidemiology, quality of life, and economic burden, including disease pathways and treatment patterns of relapsed/refractory classical Hodgkin lymphoma.2023Expert Review of Hematology
Efficacy of brentuximab vedotin and nivolumab in refractory or relapsed hodgkin lymphoma: a systematic review.2022Cureus
Effectiveness of brentuximab vedotin monotherapy in relapsed or refractory Hodgkin lymphoma: a systematic review and meta-analysis.2021Leukemia & Lymphoma
Long-term survival outcomes of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma: a systematic review and meta-analysis.2021European Review for Medical and Pharmacological Sciences
Commonly Reported Adverse Events Associated With Pediatric Immunotherapy: A Systematic Review From the Children's Oncology Group.2021Journal of Pediatric Oncology Nursing
Brentuximab vedotin for the treatment of patients with relapsed or refractory Hodgkin lymphoma after autologous stem cell transplantation.2020British Journal of Haematology
The clinical and humanistic burden of cutaneous T-cell lymphomas and response to conventional and novel therapies: results of a systematic review.2020Expert Review of Hematology
Efficacy and safety of front-line treatments for advanced Hodgkin lymphoma: a systematic literature review.2020Expert review of Hematology
A systematic review of therapeutic regimens for older patients with newly diagnosed Hodgkin lymphoma.2020Leukemia & Lymphoma
Risk of adverse events in lymphoma patients treated with brentuximab vedotin: a systematic review and meta-analysis.2020Expert opinion on drug safety

Clinical Practice Guidelines